Global Targeted Alpha-particle Therapy Market Growth (Status and Outlook) 2026-2032
The global Targeted Alpha-particle Therapy market size is predicted to grow from US$ 1161 million in 2025 to US$ 3959 million in 2032; it is expected to grow at a CAGR of 19.3% from 2026 to 2032.
Targeted Alpha-particle Therapy (TAT) is a novel radiopharmaceutical treatment technique that utilizes alpha-emitting radionuclides conjugated with targeting molecules to precisely kill tumor cells. The fundamental principle involves delivering alpha-emitting radionuclides—which possess potent cell-killing capabilities (such as Radium-223, Actinium-225, Bismuth-213, Lead-212, and Astatine-211)—to tumor tissues via antibodies, peptides, small-molecule ligands, or other biological targeting vectors. These radionuclides release high-energy alpha particles in the vicinity of cancer cells; the resulting radiation, characterized by a very short range and high Linear Energy Transfer (LET), directly disrupts the double-strand structure of cancer cell DNA, thereby inducing apoptosis or irreversible damage to the tumor cells. Compared to traditional beta-particle radiotherapy, alpha particles possess high energy and a short range of action (typically only tens of micrometers, equivalent to the diameter of a few cells), allowing for the destruction of tumor cells while minimizing radiation damage to surrounding healthy tissues.
TAT represents a significant development in the fields of precision nuclear medicine and radiopharmaceuticals; its core components include alpha-emitting radionuclides, targeting delivery molecules, and drug conjugation technology platforms. Specifically, the alpha radionuclide determines the therapeutic energy and half-life characteristics; the targeting molecule dictates the drug's ability to recognize tumor cells; and chelating agents and conjugation technologies influence radionuclide stability and in vivo distribution. Currently, this technology is primarily applied to the treatment of refractory cancers, including prostate cancer, neuroendocrine tumors, leukemia, ovarian cancer, and pancreatic cancer. Notably, Radium-223 dichloride is already used to treat bone-metastatic prostate cancer, while targeted radiopharmaceuticals based on radionuclides such as Actinium-225 and Lead-212 are becoming a focal point of clinical research.
From an industry chain perspective, the upstream sector primarily encompasses alpha radionuclide production, isotope separation and purification, nuclear reactor or accelerator facilities, and the development of chelating agents and targeting vectors. The midstream sector consists mainly of radiopharmaceutical R&D companies responsible for radionuclide labeling, drug preparation, quality control, and clinical development. The downstream sector includes hospital nuclear medicine departments, oncology treatment centers, and clinical application for patients. Due to challenges such as difficult production, complex supply chains, short half-lives, and stringent requirements for transport and storage, the number of enterprises and institutions worldwide capable of supplying alpha-emitting radionuclides at scale remains limited.
Looking ahead, the development of Targeted Alpha-particle Therapy will be driven by factors such as the growing demand for precision oncology, the accelerated R&D of innovative nuclear medicine drugs, and enhanced supply capabilities for radioactive isotopes. With continuous breakthroughs in production technologies for novel therapeutic radionuclides—such as Actinium-225 and Lead-212—alongside advancements in AI-assisted drug design, companion diagnostics, and personalized dosimetry, targeted alpha therapy is poised to emerge as a major cancer treatment modality following chemotherapy, immunotherapy, and beta-emitter therapy. This evolution will propel the radiopharmaceutical industry toward greater precision, efficiency, and personalization.
The core drivers of the Targeted Alpha-particle Therapy industry's growth stem from the rising global demand for cancer treatment and the deepening adoption of precision oncology concepts. As the global incidence of cancer rises—along with the number of patients suffering from advanced solid tumors, metastatic cancer, and refractory malignancies—traditional chemotherapy, immunotherapy, and beta-radionuclide therapies have shown limitations in efficacy or tolerability for certain patient populations. By leveraging the high linear energy transfer (LET) characteristics of alpha particles, targeted alpha-particle therapy induces DNA double-strand breaks in tumor cells over extremely short distances, achieving highly efficient cell killing while minimizing radiation exposure to surrounding healthy tissues; consequently, it demonstrates significant clinical value in treating prostate cancer, neuroendocrine tumors, hematologic malignancies, and various solid tumors.
Advancements in radiopharmaceutical R&D technologies and improved supply capabilities for key alpha-emitting radionuclides are propelling industry growth. In recent years, therapeutic alpha-emitters such as Actinium-225, Lead-212, Bismuth-213, and Astatine-211 have garnered widespread attention; continuous optimization of radionuclide production, separation and purification, radiolabeling, and chelator technologies has enhanced the feasibility of developing alpha-emitter-based drugs. Simultaneously, the development of targeting agents—including antibodies, peptides, and small-molecule ligands—along with novel delivery platforms, enables alpha-emitters to target tumor cells with greater precision and improves control over drug distribution within the body. With the maturation of nuclear medicine infrastructure and an increasing number of clinical trials, targeted alpha-particle therapy is transitioning from early-stage scientific research toward commercial application.
Furthermore, targeted alpha-particle therapy is poised to expand into a broader range of cancer types and evolve toward combination therapies and intelligent, data-driven approaches. Future R&D will shift from developing drugs for single indications to creating radiopharmaceutical platforms that cover a wider array of cancers, such as prostate, breast, pancreatic, and ovarian cancers, as well as gliomas. Additionally, alpha-emitter therapy is expected to integrate with immunotherapy, targeted therapy, and genetic testing technologies, enabling highly personalized treatment plans through patient screening based on molecular biomarkers and precision dosimetry. Developments in AI-assisted drug screening, image-guided dose assessment, and companion diagnostics will further enhance therapeutic outcomes and the efficiency of clinical application.
Report Scope
LPI (LP Information)' newest research report, the “Targeted Alpha-particle Therapy Industry Forecast” looks at past sales and reviews total world Targeted Alpha-particle Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Alpha-particle Therapy sales for 2026 through 2032. With Targeted Alpha-particle Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Alpha-particle Therapy industry.
This Insight Report provides a comprehensive analysis of the global Targeted Alpha-particle Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Alpha-particle Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Alpha-particle Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Alpha-particle Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Alpha-particle Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Alpha-particle Therapy market by product type, application, key players and key regions and countries.
Targeted Alpha-particle Therapy (TAT) is a novel radiopharmaceutical treatment technique that utilizes alpha-emitting radionuclides conjugated with targeting molecules to precisely kill tumor cells. The fundamental principle involves delivering alpha-emitting radionuclides—which possess potent cell-killing capabilities (such as Radium-223, Actinium-225, Bismuth-213, Lead-212, and Astatine-211)—to tumor tissues via antibodies, peptides, small-molecule ligands, or other biological targeting vectors. These radionuclides release high-energy alpha particles in the vicinity of cancer cells; the resulting radiation, characterized by a very short range and high Linear Energy Transfer (LET), directly disrupts the double-strand structure of cancer cell DNA, thereby inducing apoptosis or irreversible damage to the tumor cells. Compared to traditional beta-particle radiotherapy, alpha particles possess high energy and a short range of action (typically only tens of micrometers, equivalent to the diameter of a few cells), allowing for the destruction of tumor cells while minimizing radiation damage to surrounding healthy tissues.
TAT represents a significant development in the fields of precision nuclear medicine and radiopharmaceuticals; its core components include alpha-emitting radionuclides, targeting delivery molecules, and drug conjugation technology platforms. Specifically, the alpha radionuclide determines the therapeutic energy and half-life characteristics; the targeting molecule dictates the drug's ability to recognize tumor cells; and chelating agents and conjugation technologies influence radionuclide stability and in vivo distribution. Currently, this technology is primarily applied to the treatment of refractory cancers, including prostate cancer, neuroendocrine tumors, leukemia, ovarian cancer, and pancreatic cancer. Notably, Radium-223 dichloride is already used to treat bone-metastatic prostate cancer, while targeted radiopharmaceuticals based on radionuclides such as Actinium-225 and Lead-212 are becoming a focal point of clinical research.
From an industry chain perspective, the upstream sector primarily encompasses alpha radionuclide production, isotope separation and purification, nuclear reactor or accelerator facilities, and the development of chelating agents and targeting vectors. The midstream sector consists mainly of radiopharmaceutical R&D companies responsible for radionuclide labeling, drug preparation, quality control, and clinical development. The downstream sector includes hospital nuclear medicine departments, oncology treatment centers, and clinical application for patients. Due to challenges such as difficult production, complex supply chains, short half-lives, and stringent requirements for transport and storage, the number of enterprises and institutions worldwide capable of supplying alpha-emitting radionuclides at scale remains limited.
Looking ahead, the development of Targeted Alpha-particle Therapy will be driven by factors such as the growing demand for precision oncology, the accelerated R&D of innovative nuclear medicine drugs, and enhanced supply capabilities for radioactive isotopes. With continuous breakthroughs in production technologies for novel therapeutic radionuclides—such as Actinium-225 and Lead-212—alongside advancements in AI-assisted drug design, companion diagnostics, and personalized dosimetry, targeted alpha therapy is poised to emerge as a major cancer treatment modality following chemotherapy, immunotherapy, and beta-emitter therapy. This evolution will propel the radiopharmaceutical industry toward greater precision, efficiency, and personalization.
The core drivers of the Targeted Alpha-particle Therapy industry's growth stem from the rising global demand for cancer treatment and the deepening adoption of precision oncology concepts. As the global incidence of cancer rises—along with the number of patients suffering from advanced solid tumors, metastatic cancer, and refractory malignancies—traditional chemotherapy, immunotherapy, and beta-radionuclide therapies have shown limitations in efficacy or tolerability for certain patient populations. By leveraging the high linear energy transfer (LET) characteristics of alpha particles, targeted alpha-particle therapy induces DNA double-strand breaks in tumor cells over extremely short distances, achieving highly efficient cell killing while minimizing radiation exposure to surrounding healthy tissues; consequently, it demonstrates significant clinical value in treating prostate cancer, neuroendocrine tumors, hematologic malignancies, and various solid tumors.
Advancements in radiopharmaceutical R&D technologies and improved supply capabilities for key alpha-emitting radionuclides are propelling industry growth. In recent years, therapeutic alpha-emitters such as Actinium-225, Lead-212, Bismuth-213, and Astatine-211 have garnered widespread attention; continuous optimization of radionuclide production, separation and purification, radiolabeling, and chelator technologies has enhanced the feasibility of developing alpha-emitter-based drugs. Simultaneously, the development of targeting agents—including antibodies, peptides, and small-molecule ligands—along with novel delivery platforms, enables alpha-emitters to target tumor cells with greater precision and improves control over drug distribution within the body. With the maturation of nuclear medicine infrastructure and an increasing number of clinical trials, targeted alpha-particle therapy is transitioning from early-stage scientific research toward commercial application.
Furthermore, targeted alpha-particle therapy is poised to expand into a broader range of cancer types and evolve toward combination therapies and intelligent, data-driven approaches. Future R&D will shift from developing drugs for single indications to creating radiopharmaceutical platforms that cover a wider array of cancers, such as prostate, breast, pancreatic, and ovarian cancers, as well as gliomas. Additionally, alpha-emitter therapy is expected to integrate with immunotherapy, targeted therapy, and genetic testing technologies, enabling highly personalized treatment plans through patient screening based on molecular biomarkers and precision dosimetry. Developments in AI-assisted drug screening, image-guided dose assessment, and companion diagnostics will further enhance therapeutic outcomes and the efficiency of clinical application.
Report Scope
LPI (LP Information)' newest research report, the “Targeted Alpha-particle Therapy Industry Forecast” looks at past sales and reviews total world Targeted Alpha-particle Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Alpha-particle Therapy sales for 2026 through 2032. With Targeted Alpha-particle Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Alpha-particle Therapy industry.
This Insight Report provides a comprehensive analysis of the global Targeted Alpha-particle Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Alpha-particle Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Alpha-particle Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Alpha-particle Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Alpha-particle Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Alpha-particle Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Actinium-225
- Astatine-211
- Lead-212
- Bismuth-213
- Others
Segmentation by Targeted Carriers:
- Antibody-based ? Therapy
- Peptide Receptor Radionuclide Therapy
- Small Molecule ? Therapy
- Nano-carrier ? Therapy
- Cell-based ? Therapy
Segmentation by Therapeutic Target:
- PSMA-targeted Alpha Therapy
- SSTR-targeted Alpha Therapy
- CD33/CD45-targeted Alpha Therapy
- HER2-targeted Alpha Therapy
- EGFR-targeted Alpha Therapy
- Others
Segmentation by Drug Delivery Method:
- Systemic Administration
- Local Administration
- Radioimmunotherapy
- Combination Therapy Alpha Drugs
Segmentation by Application:
- Immunotherapy
- Peritoneal Carcinomas
- Bone Metastases
- Leukaemia
- Melanomas
- Solid Tumours
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bayer
- Orano Med
- Oncoinvent AS
- Perspective Therapeutics
- Ablaze Pharma
- ARTBIO
- Fusion Pharmaceuticals(AstraZeneca)
- AlphaGen Therapeutics
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Alpha-particle Therapy Market Size (2021-2032)
2.1.2 Targeted Alpha-particle Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted Alpha-particle Therapy by Country/Region (2021, 2025 & 2032)
2.2 Targeted Alpha-particle Therapy Segment by Type
2.2.1 Actinium-225
2.2.2 Astatine-211
2.2.3 Lead-212
2.2.4 Bismuth-213
2.2.5 Others
2.2.6 Targeted Alpha-particle Therapy Market Size by Type
2.2.6.1 Targeted Alpha-particle Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
2.3 Targeted Alpha-particle Therapy Segment by Targeted Carriers
2.3.1 Antibody-based ? Therapy
2.3.2 Peptide Receptor Radionuclide Therapy
2.3.3 Small Molecule ? Therapy
2.3.4 Nano-carrier ? Therapy
2.3.5 Cell-based ? Therapy
2.3.6 Targeted Alpha-particle Therapy Market Size by Targeted Carriers
2.3.6.1 Targeted Alpha-particle Therapy Market Size CAGR by Targeted Carriers (2021 VS 2025 VS 2032)
2.3.6.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2021-2026)
2.4 Targeted Alpha-particle Therapy Segment by Therapeutic Target
2.4.1 PSMA-targeted Alpha Therapy
2.4.2 SSTR-targeted Alpha Therapy
2.4.3 CD33/CD45-targeted Alpha Therapy
2.4.4 HER2-targeted Alpha Therapy
2.4.5 EGFR-targeted Alpha Therapy
2.4.6 Others
2.4.7 Targeted Alpha-particle Therapy Market Size by Therapeutic Target
2.4.7.1 Targeted Alpha-particle Therapy Market Size CAGR by Therapeutic Target (2021 VS 2025 VS 2032)
2.4.7.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2021-2026)
2.5 Targeted Alpha-particle Therapy Segment by Drug Delivery Method
2.5.1 Systemic Administration
2.5.2 Local Administration
2.5.3 Radioimmunotherapy
2.5.4 Combination Therapy Alpha Drugs
2.5.5 Targeted Alpha-particle Therapy Market Size by Drug Delivery Method
2.5.5.1 Targeted Alpha-particle Therapy Market Size CAGR by Drug Delivery Method (2021 VS 2025 VS 2032)
2.5.5.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2021-2026)
2.6 Targeted Alpha-particle Therapy Segment by Application
2.6.1 Immunotherapy
2.6.2 Peritoneal Carcinomas
2.6.3 Bone Metastases
2.6.4 Leukaemia
2.6.5 Melanomas
2.6.6 Solid Tumours
2.6.7 Targeted Alpha-particle Therapy Market Size by Application
2.6.7.1 Targeted Alpha-particle Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.6.7.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
3 TARGETED ALPHA-PARTICLE THERAPY MARKET SIZE BY PLAYER
3.1 Targeted Alpha-particle Therapy Market Size Market Share by Player
3.1.1 Global Targeted Alpha-particle Therapy Revenue by Player (2021-2026)
3.1.2 Global Targeted Alpha-particle Therapy Revenue Market Share by Player (2021-2026)
3.2 Global Targeted Alpha-particle Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED ALPHA-PARTICLE THERAPY BY REGION
4.1 Targeted Alpha-particle Therapy Market Size by Region (2021-2026)
4.2 Global Targeted Alpha-particle Therapy Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
4.4 APAC Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
4.5 Europe Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted Alpha-particle Therapy Market Size by Country (2021-2026)
5.2 Americas Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
5.3 Americas Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Alpha-particle Therapy Market Size by Region (2021-2026)
6.2 APAC Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
6.3 APAC Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Alpha-particle Therapy Market Size by Country (2021-2026)
7.2 Europe Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
7.3 Europe Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Alpha-particle Therapy by Region (2021-2026)
8.2 Middle East & Africa Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED ALPHA-PARTICLE THERAPY MARKET FORECAST
10.1 Global Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.1.1 Global Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.1.2 Americas Targeted Alpha-particle Therapy Forecast
10.1.3 APAC Targeted Alpha-particle Therapy Forecast
10.1.4 Europe Targeted Alpha-particle Therapy Forecast
10.1.5 Middle East & Africa Targeted Alpha-particle Therapy Forecast
10.2 Americas Targeted Alpha-particle Therapy Forecast by Country (2027-2032)
10.2.1 United States Market Targeted Alpha-particle Therapy Forecast
10.2.2 Canada Market Targeted Alpha-particle Therapy Forecast
10.2.3 Mexico Market Targeted Alpha-particle Therapy Forecast
10.2.4 Brazil Market Targeted Alpha-particle Therapy Forecast
10.3 APAC Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.3.1 China Targeted Alpha-particle Therapy Market Forecast
10.3.2 Japan Market Targeted Alpha-particle Therapy Forecast
10.3.3 Korea Market Targeted Alpha-particle Therapy Forecast
10.3.4 Southeast Asia Market Targeted Alpha-particle Therapy Forecast
10.3.5 India Market Targeted Alpha-particle Therapy Forecast
10.3.6 Australia Market Targeted Alpha-particle Therapy Forecast
10.4 Europe Targeted Alpha-particle Therapy Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted Alpha-particle Therapy Forecast
10.4.2 France Market Targeted Alpha-particle Therapy Forecast
10.4.3 UK Market Targeted Alpha-particle Therapy Forecast
10.4.4 Italy Market Targeted Alpha-particle Therapy Forecast
10.4.5 Russia Market Targeted Alpha-particle Therapy Forecast
10.5 Middle East & Africa Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted Alpha-particle Therapy Forecast
10.5.2 South Africa Market Targeted Alpha-particle Therapy Forecast
10.5.3 Israel Market Targeted Alpha-particle Therapy Forecast
10.5.4 Turkey Market Targeted Alpha-particle Therapy Forecast
10.6 Global Targeted Alpha-particle Therapy Forecast by Type (2027-2032)
10.7 Global Targeted Alpha-particle Therapy Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted Alpha-particle Therapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Targeted Alpha-particle Therapy Product Offered
11.1.3 Bayer Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Orano Med
11.2.1 Orano Med Company Information
11.2.2 Orano Med Targeted Alpha-particle Therapy Product Offered
11.2.3 Orano Med Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Orano Med Main Business Overview
11.2.5 Orano Med Latest Developments
11.3 Oncoinvent AS
11.3.1 Oncoinvent AS Company Information
11.3.2 Oncoinvent AS Targeted Alpha-particle Therapy Product Offered
11.3.3 Oncoinvent AS Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Oncoinvent AS Main Business Overview
11.3.5 Oncoinvent AS Latest Developments
11.4 Perspective Therapeutics
11.4.1 Perspective Therapeutics Company Information
11.4.2 Perspective Therapeutics Targeted Alpha-particle Therapy Product Offered
11.4.3 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Perspective Therapeutics Main Business Overview
11.4.5 Perspective Therapeutics Latest Developments
11.5 Ablaze Pharma
11.5.1 Ablaze Pharma Company Information
11.5.2 Ablaze Pharma Targeted Alpha-particle Therapy Product Offered
11.5.3 Ablaze Pharma Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Ablaze Pharma Main Business Overview
11.5.5 Ablaze Pharma Latest Developments
11.6 ARTBIO
11.6.1 ARTBIO Company Information
11.6.2 ARTBIO Targeted Alpha-particle Therapy Product Offered
11.6.3 ARTBIO Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 ARTBIO Main Business Overview
11.6.5 ARTBIO Latest Developments
11.7 Fusion Pharmaceuticals(AstraZeneca)
11.7.1 Fusion Pharmaceuticals(AstraZeneca) Company Information
11.7.2 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product Offered
11.7.3 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Fusion Pharmaceuticals(AstraZeneca) Main Business Overview
11.7.5 Fusion Pharmaceuticals(AstraZeneca) Latest Developments
11.8 AlphaGen Therapeutics
11.8.1 AlphaGen Therapeutics Company Information
11.8.2 AlphaGen Therapeutics Targeted Alpha-particle Therapy Product Offered
11.8.3 AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 AlphaGen Therapeutics Main Business Overview
11.8.5 AlphaGen Therapeutics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Alpha-particle Therapy Market Size (2021-2032)
2.1.2 Targeted Alpha-particle Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted Alpha-particle Therapy by Country/Region (2021, 2025 & 2032)
2.2 Targeted Alpha-particle Therapy Segment by Type
2.2.1 Actinium-225
2.2.2 Astatine-211
2.2.3 Lead-212
2.2.4 Bismuth-213
2.2.5 Others
2.2.6 Targeted Alpha-particle Therapy Market Size by Type
2.2.6.1 Targeted Alpha-particle Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
2.3 Targeted Alpha-particle Therapy Segment by Targeted Carriers
2.3.1 Antibody-based ? Therapy
2.3.2 Peptide Receptor Radionuclide Therapy
2.3.3 Small Molecule ? Therapy
2.3.4 Nano-carrier ? Therapy
2.3.5 Cell-based ? Therapy
2.3.6 Targeted Alpha-particle Therapy Market Size by Targeted Carriers
2.3.6.1 Targeted Alpha-particle Therapy Market Size CAGR by Targeted Carriers (2021 VS 2025 VS 2032)
2.3.6.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2021-2026)
2.4 Targeted Alpha-particle Therapy Segment by Therapeutic Target
2.4.1 PSMA-targeted Alpha Therapy
2.4.2 SSTR-targeted Alpha Therapy
2.4.3 CD33/CD45-targeted Alpha Therapy
2.4.4 HER2-targeted Alpha Therapy
2.4.5 EGFR-targeted Alpha Therapy
2.4.6 Others
2.4.7 Targeted Alpha-particle Therapy Market Size by Therapeutic Target
2.4.7.1 Targeted Alpha-particle Therapy Market Size CAGR by Therapeutic Target (2021 VS 2025 VS 2032)
2.4.7.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2021-2026)
2.5 Targeted Alpha-particle Therapy Segment by Drug Delivery Method
2.5.1 Systemic Administration
2.5.2 Local Administration
2.5.3 Radioimmunotherapy
2.5.4 Combination Therapy Alpha Drugs
2.5.5 Targeted Alpha-particle Therapy Market Size by Drug Delivery Method
2.5.5.1 Targeted Alpha-particle Therapy Market Size CAGR by Drug Delivery Method (2021 VS 2025 VS 2032)
2.5.5.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2021-2026)
2.6 Targeted Alpha-particle Therapy Segment by Application
2.6.1 Immunotherapy
2.6.2 Peritoneal Carcinomas
2.6.3 Bone Metastases
2.6.4 Leukaemia
2.6.5 Melanomas
2.6.6 Solid Tumours
2.6.7 Targeted Alpha-particle Therapy Market Size by Application
2.6.7.1 Targeted Alpha-particle Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.6.7.2 Global Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
3 TARGETED ALPHA-PARTICLE THERAPY MARKET SIZE BY PLAYER
3.1 Targeted Alpha-particle Therapy Market Size Market Share by Player
3.1.1 Global Targeted Alpha-particle Therapy Revenue by Player (2021-2026)
3.1.2 Global Targeted Alpha-particle Therapy Revenue Market Share by Player (2021-2026)
3.2 Global Targeted Alpha-particle Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED ALPHA-PARTICLE THERAPY BY REGION
4.1 Targeted Alpha-particle Therapy Market Size by Region (2021-2026)
4.2 Global Targeted Alpha-particle Therapy Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
4.4 APAC Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
4.5 Europe Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted Alpha-particle Therapy Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted Alpha-particle Therapy Market Size by Country (2021-2026)
5.2 Americas Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
5.3 Americas Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Alpha-particle Therapy Market Size by Region (2021-2026)
6.2 APAC Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
6.3 APAC Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Alpha-particle Therapy Market Size by Country (2021-2026)
7.2 Europe Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
7.3 Europe Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Alpha-particle Therapy by Region (2021-2026)
8.2 Middle East & Africa Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED ALPHA-PARTICLE THERAPY MARKET FORECAST
10.1 Global Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.1.1 Global Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.1.2 Americas Targeted Alpha-particle Therapy Forecast
10.1.3 APAC Targeted Alpha-particle Therapy Forecast
10.1.4 Europe Targeted Alpha-particle Therapy Forecast
10.1.5 Middle East & Africa Targeted Alpha-particle Therapy Forecast
10.2 Americas Targeted Alpha-particle Therapy Forecast by Country (2027-2032)
10.2.1 United States Market Targeted Alpha-particle Therapy Forecast
10.2.2 Canada Market Targeted Alpha-particle Therapy Forecast
10.2.3 Mexico Market Targeted Alpha-particle Therapy Forecast
10.2.4 Brazil Market Targeted Alpha-particle Therapy Forecast
10.3 APAC Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.3.1 China Targeted Alpha-particle Therapy Market Forecast
10.3.2 Japan Market Targeted Alpha-particle Therapy Forecast
10.3.3 Korea Market Targeted Alpha-particle Therapy Forecast
10.3.4 Southeast Asia Market Targeted Alpha-particle Therapy Forecast
10.3.5 India Market Targeted Alpha-particle Therapy Forecast
10.3.6 Australia Market Targeted Alpha-particle Therapy Forecast
10.4 Europe Targeted Alpha-particle Therapy Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted Alpha-particle Therapy Forecast
10.4.2 France Market Targeted Alpha-particle Therapy Forecast
10.4.3 UK Market Targeted Alpha-particle Therapy Forecast
10.4.4 Italy Market Targeted Alpha-particle Therapy Forecast
10.4.5 Russia Market Targeted Alpha-particle Therapy Forecast
10.5 Middle East & Africa Targeted Alpha-particle Therapy Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted Alpha-particle Therapy Forecast
10.5.2 South Africa Market Targeted Alpha-particle Therapy Forecast
10.5.3 Israel Market Targeted Alpha-particle Therapy Forecast
10.5.4 Turkey Market Targeted Alpha-particle Therapy Forecast
10.6 Global Targeted Alpha-particle Therapy Forecast by Type (2027-2032)
10.7 Global Targeted Alpha-particle Therapy Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted Alpha-particle Therapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Targeted Alpha-particle Therapy Product Offered
11.1.3 Bayer Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Orano Med
11.2.1 Orano Med Company Information
11.2.2 Orano Med Targeted Alpha-particle Therapy Product Offered
11.2.3 Orano Med Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Orano Med Main Business Overview
11.2.5 Orano Med Latest Developments
11.3 Oncoinvent AS
11.3.1 Oncoinvent AS Company Information
11.3.2 Oncoinvent AS Targeted Alpha-particle Therapy Product Offered
11.3.3 Oncoinvent AS Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Oncoinvent AS Main Business Overview
11.3.5 Oncoinvent AS Latest Developments
11.4 Perspective Therapeutics
11.4.1 Perspective Therapeutics Company Information
11.4.2 Perspective Therapeutics Targeted Alpha-particle Therapy Product Offered
11.4.3 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Perspective Therapeutics Main Business Overview
11.4.5 Perspective Therapeutics Latest Developments
11.5 Ablaze Pharma
11.5.1 Ablaze Pharma Company Information
11.5.2 Ablaze Pharma Targeted Alpha-particle Therapy Product Offered
11.5.3 Ablaze Pharma Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Ablaze Pharma Main Business Overview
11.5.5 Ablaze Pharma Latest Developments
11.6 ARTBIO
11.6.1 ARTBIO Company Information
11.6.2 ARTBIO Targeted Alpha-particle Therapy Product Offered
11.6.3 ARTBIO Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 ARTBIO Main Business Overview
11.6.5 ARTBIO Latest Developments
11.7 Fusion Pharmaceuticals(AstraZeneca)
11.7.1 Fusion Pharmaceuticals(AstraZeneca) Company Information
11.7.2 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product Offered
11.7.3 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Fusion Pharmaceuticals(AstraZeneca) Main Business Overview
11.7.5 Fusion Pharmaceuticals(AstraZeneca) Latest Developments
11.8 AlphaGen Therapeutics
11.8.1 AlphaGen Therapeutics Company Information
11.8.2 AlphaGen Therapeutics Targeted Alpha-particle Therapy Product Offered
11.8.3 AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 AlphaGen Therapeutics Main Business Overview
11.8.5 AlphaGen Therapeutics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Alpha-particle Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted Alpha-particle Therapy Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Actinium-225
Table 4. Major Players of Astatine-211
Table 5. Major Players of Lead-212
Table 6. Major Players of Bismuth-213
Table 7. Major Players of Others
Table 8. Targeted Alpha-particle Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Antibody-based ? Therapy
Table 12. Major Players of Peptide Receptor Radionuclide Therapy
Table 13. Major Players of Small Molecule ? Therapy
Table 14. Major Players of Nano-carrier ? Therapy
Table 15. Major Players of Cell-based ? Therapy
Table 16. Targeted Alpha-particle Therapy Market Size CAGR by Targeted Carriers (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2021-2026) & ($ millions)
Table 18. Global Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2021-2026)
Table 19. Major Players of PSMA-targeted Alpha Therapy
Table 20. Major Players of SSTR-targeted Alpha Therapy
Table 21. Major Players of CD33/CD45-targeted Alpha Therapy
Table 22. Major Players of HER2-targeted Alpha Therapy
Table 23. Major Players of EGFR-targeted Alpha Therapy
Table 24. Major Players of Others
Table 25. Targeted Alpha-particle Therapy Market Size CAGR by Therapeutic Target (2021 VS 2025 VS 2032) & ($ millions)
Table 26. Global Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2021-2026) & ($ millions)
Table 27. Global Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2021-2026)
Table 28. Major Players of Systemic Administration
Table 29. Major Players of Local Administration
Table 30. Major Players of Radioimmunotherapy
Table 31. Major Players of Combination Therapy Alpha Drugs
Table 32. Targeted Alpha-particle Therapy Market Size CAGR by Drug Delivery Method (2021 VS 2025 VS 2032) & ($ millions)
Table 33. Global Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2021-2026) & ($ millions)
Table 34. Global Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2021-2026)
Table 35. Targeted Alpha-particle Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 36. Global Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 37. Global Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Table 38. Global Targeted Alpha-particle Therapy Revenue by Player (2021-2026) & ($ millions)
Table 39. Global Targeted Alpha-particle Therapy Revenue Market Share by Player (2021-2026)
Table 40. Targeted Alpha-particle Therapy Key Players Head office and Products Offered
Table 41. Targeted Alpha-particle Therapy Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 42. New Products and Potential Entrants
Table 43. Mergers & Acquisitions, Expansion
Table 44. Global Targeted Alpha-particle Therapy Market Size by Region (2021-2026) & ($ millions)
Table 45. Global Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Table 46. Global Targeted Alpha-particle Therapy Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Targeted Alpha-particle Therapy Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Targeted Alpha-particle Therapy Market Size by Country (2021-2026) & ($ millions)
Table 49. Americas Targeted Alpha-particle Therapy Market Size Market Share by Country (2021-2026)
Table 50. Americas Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 51. Americas Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Table 52. Americas Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 53. Americas Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Table 54. APAC Targeted Alpha-particle Therapy Market Size by Region (2021-2026) & ($ millions)
Table 55. APAC Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Table 56. APAC Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 57. APAC Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 58. Europe Targeted Alpha-particle Therapy Market Size by Country (2021-2026) & ($ millions)
Table 59. Europe Targeted Alpha-particle Therapy Market Size Market Share by Country (2021-2026)
Table 60. Europe Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 61. Europe Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 62. Middle East & Africa Targeted Alpha-particle Therapy Market Size by Region (2021-2026) & ($ millions)
Table 63. Middle East & Africa Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 64. Middle East & Africa Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 65. Key Market Drivers & Growth Opportunities of Targeted Alpha-particle Therapy
Table 66. Key Market Challenges & Risks of Targeted Alpha-particle Therapy
Table 67. Key Industry Trends of Targeted Alpha-particle Therapy
Table 68. Global Targeted Alpha-particle Therapy Market Size Forecast by Region (2027-2032) & ($ millions)
Table 69. Global Targeted Alpha-particle Therapy Market Size Market Share Forecast by Region (2027-2032)
Table 70. Global Targeted Alpha-particle Therapy Market Size Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Targeted Alpha-particle Therapy Market Size Forecast by Application (2027-2032) & ($ millions)
Table 72. Bayer Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 73. Bayer Targeted Alpha-particle Therapy Product Offered
Table 74. Bayer Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Bayer Main Business
Table 76. Bayer Latest Developments
Table 77. Orano Med Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 78. Orano Med Targeted Alpha-particle Therapy Product Offered
Table 79. Orano Med Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Orano Med Main Business
Table 81. Orano Med Latest Developments
Table 82. Oncoinvent AS Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 83. Oncoinvent AS Targeted Alpha-particle Therapy Product Offered
Table 84. Oncoinvent AS Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Oncoinvent AS Main Business
Table 86. Oncoinvent AS Latest Developments
Table 87. Perspective Therapeutics Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 88. Perspective Therapeutics Targeted Alpha-particle Therapy Product Offered
Table 89. Perspective Therapeutics Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Perspective Therapeutics Main Business
Table 91. Perspective Therapeutics Latest Developments
Table 92. Ablaze Pharma Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 93. Ablaze Pharma Targeted Alpha-particle Therapy Product Offered
Table 94. Ablaze Pharma Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Ablaze Pharma Main Business
Table 96. Ablaze Pharma Latest Developments
Table 97. ARTBIO Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 98. ARTBIO Targeted Alpha-particle Therapy Product Offered
Table 99. ARTBIO Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. ARTBIO Main Business
Table 101. ARTBIO Latest Developments
Table 102. Fusion Pharmaceuticals(AstraZeneca) Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 103. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product Offered
Table 104. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Fusion Pharmaceuticals(AstraZeneca) Main Business
Table 106. Fusion Pharmaceuticals(AstraZeneca) Latest Developments
Table 107. AlphaGen Therapeutics Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 108. AlphaGen Therapeutics Targeted Alpha-particle Therapy Product Offered
Table 109. AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. AlphaGen Therapeutics Main Business
Table 111. AlphaGen Therapeutics Latest Developments
Table 1. Targeted Alpha-particle Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted Alpha-particle Therapy Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Actinium-225
Table 4. Major Players of Astatine-211
Table 5. Major Players of Lead-212
Table 6. Major Players of Bismuth-213
Table 7. Major Players of Others
Table 8. Targeted Alpha-particle Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Antibody-based ? Therapy
Table 12. Major Players of Peptide Receptor Radionuclide Therapy
Table 13. Major Players of Small Molecule ? Therapy
Table 14. Major Players of Nano-carrier ? Therapy
Table 15. Major Players of Cell-based ? Therapy
Table 16. Targeted Alpha-particle Therapy Market Size CAGR by Targeted Carriers (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2021-2026) & ($ millions)
Table 18. Global Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2021-2026)
Table 19. Major Players of PSMA-targeted Alpha Therapy
Table 20. Major Players of SSTR-targeted Alpha Therapy
Table 21. Major Players of CD33/CD45-targeted Alpha Therapy
Table 22. Major Players of HER2-targeted Alpha Therapy
Table 23. Major Players of EGFR-targeted Alpha Therapy
Table 24. Major Players of Others
Table 25. Targeted Alpha-particle Therapy Market Size CAGR by Therapeutic Target (2021 VS 2025 VS 2032) & ($ millions)
Table 26. Global Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2021-2026) & ($ millions)
Table 27. Global Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2021-2026)
Table 28. Major Players of Systemic Administration
Table 29. Major Players of Local Administration
Table 30. Major Players of Radioimmunotherapy
Table 31. Major Players of Combination Therapy Alpha Drugs
Table 32. Targeted Alpha-particle Therapy Market Size CAGR by Drug Delivery Method (2021 VS 2025 VS 2032) & ($ millions)
Table 33. Global Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2021-2026) & ($ millions)
Table 34. Global Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2021-2026)
Table 35. Targeted Alpha-particle Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 36. Global Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 37. Global Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Table 38. Global Targeted Alpha-particle Therapy Revenue by Player (2021-2026) & ($ millions)
Table 39. Global Targeted Alpha-particle Therapy Revenue Market Share by Player (2021-2026)
Table 40. Targeted Alpha-particle Therapy Key Players Head office and Products Offered
Table 41. Targeted Alpha-particle Therapy Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 42. New Products and Potential Entrants
Table 43. Mergers & Acquisitions, Expansion
Table 44. Global Targeted Alpha-particle Therapy Market Size by Region (2021-2026) & ($ millions)
Table 45. Global Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Table 46. Global Targeted Alpha-particle Therapy Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Targeted Alpha-particle Therapy Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Targeted Alpha-particle Therapy Market Size by Country (2021-2026) & ($ millions)
Table 49. Americas Targeted Alpha-particle Therapy Market Size Market Share by Country (2021-2026)
Table 50. Americas Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 51. Americas Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Table 52. Americas Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 53. Americas Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Table 54. APAC Targeted Alpha-particle Therapy Market Size by Region (2021-2026) & ($ millions)
Table 55. APAC Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Table 56. APAC Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 57. APAC Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 58. Europe Targeted Alpha-particle Therapy Market Size by Country (2021-2026) & ($ millions)
Table 59. Europe Targeted Alpha-particle Therapy Market Size Market Share by Country (2021-2026)
Table 60. Europe Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 61. Europe Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 62. Middle East & Africa Targeted Alpha-particle Therapy Market Size by Region (2021-2026) & ($ millions)
Table 63. Middle East & Africa Targeted Alpha-particle Therapy Market Size by Type (2021-2026) & ($ millions)
Table 64. Middle East & Africa Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & ($ millions)
Table 65. Key Market Drivers & Growth Opportunities of Targeted Alpha-particle Therapy
Table 66. Key Market Challenges & Risks of Targeted Alpha-particle Therapy
Table 67. Key Industry Trends of Targeted Alpha-particle Therapy
Table 68. Global Targeted Alpha-particle Therapy Market Size Forecast by Region (2027-2032) & ($ millions)
Table 69. Global Targeted Alpha-particle Therapy Market Size Market Share Forecast by Region (2027-2032)
Table 70. Global Targeted Alpha-particle Therapy Market Size Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Targeted Alpha-particle Therapy Market Size Forecast by Application (2027-2032) & ($ millions)
Table 72. Bayer Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 73. Bayer Targeted Alpha-particle Therapy Product Offered
Table 74. Bayer Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Bayer Main Business
Table 76. Bayer Latest Developments
Table 77. Orano Med Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 78. Orano Med Targeted Alpha-particle Therapy Product Offered
Table 79. Orano Med Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Orano Med Main Business
Table 81. Orano Med Latest Developments
Table 82. Oncoinvent AS Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 83. Oncoinvent AS Targeted Alpha-particle Therapy Product Offered
Table 84. Oncoinvent AS Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Oncoinvent AS Main Business
Table 86. Oncoinvent AS Latest Developments
Table 87. Perspective Therapeutics Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 88. Perspective Therapeutics Targeted Alpha-particle Therapy Product Offered
Table 89. Perspective Therapeutics Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Perspective Therapeutics Main Business
Table 91. Perspective Therapeutics Latest Developments
Table 92. Ablaze Pharma Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 93. Ablaze Pharma Targeted Alpha-particle Therapy Product Offered
Table 94. Ablaze Pharma Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Ablaze Pharma Main Business
Table 96. Ablaze Pharma Latest Developments
Table 97. ARTBIO Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 98. ARTBIO Targeted Alpha-particle Therapy Product Offered
Table 99. ARTBIO Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. ARTBIO Main Business
Table 101. ARTBIO Latest Developments
Table 102. Fusion Pharmaceuticals(AstraZeneca) Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 103. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product Offered
Table 104. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Fusion Pharmaceuticals(AstraZeneca) Main Business
Table 106. Fusion Pharmaceuticals(AstraZeneca) Latest Developments
Table 107. AlphaGen Therapeutics Details, Company Type, Targeted Alpha-particle Therapy Area Served and Its Competitors
Table 108. AlphaGen Therapeutics Targeted Alpha-particle Therapy Product Offered
Table 109. AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. AlphaGen Therapeutics Main Business
Table 111. AlphaGen Therapeutics Latest Developments
LIST OF FIGURES
Figure 1. Targeted Alpha-particle Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Alpha-particle Therapy Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted Alpha-particle Therapy Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted Alpha-particle Therapy Sales Market Share by Country/Region (2025)
Figure 8. Targeted Alpha-particle Therapy Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted Alpha-particle Therapy Market Size Market Share by Type in 2025
Figure 10. Global Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers in 2025
Figure 11. Global Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target in 2025
Figure 12. Global Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method in 2025
Figure 13. Targeted Alpha-particle Therapy in Immunotherapy
Figure 14. Global Targeted Alpha-particle Therapy Market: Immunotherapy (2021-2026) & ($ millions)
Figure 15. Targeted Alpha-particle Therapy in Peritoneal Carcinomas
Figure 16. Global Targeted Alpha-particle Therapy Market: Peritoneal Carcinomas (2021-2026) & ($ millions)
Figure 17. Targeted Alpha-particle Therapy in Bone Metastases
Figure 18. Global Targeted Alpha-particle Therapy Market: Bone Metastases (2021-2026) & ($ millions)
Figure 19. Targeted Alpha-particle Therapy in Leukaemia
Figure 20. Global Targeted Alpha-particle Therapy Market: Leukaemia (2021-2026) & ($ millions)
Figure 21. Targeted Alpha-particle Therapy in Melanomas
Figure 22. Global Targeted Alpha-particle Therapy Market: Melanomas (2021-2026) & ($ millions)
Figure 23. Targeted Alpha-particle Therapy in Solid Tumours
Figure 24. Global Targeted Alpha-particle Therapy Market: Solid Tumours (2021-2026) & ($ millions)
Figure 25. Global Targeted Alpha-particle Therapy Market Size Market Share by Application in 2025
Figure 26. Global Targeted Alpha-particle Therapy Revenue Market Share by Player in 2025
Figure 27. Global Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Figure 28. Americas Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 29. APAC Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 30. Europe Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 31. Middle East & Africa Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 32. Americas Targeted Alpha-particle Therapy Value Market Share by Country in 2025
Figure 33. United States Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 34. Canada Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 35. Mexico Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 36. Brazil Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 37. APAC Targeted Alpha-particle Therapy Market Size Market Share by Region in 2025
Figure 38. APAC Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Figure 39. APAC Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Figure 40. China Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 41. Japan Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 42. South Korea Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 43. Southeast Asia Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 44. India Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 45. Australia Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 46. Europe Targeted Alpha-particle Therapy Market Size Market Share by Country in 2025
Figure 47. Europe Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Figure 48. Europe Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Figure 49. Germany Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 50. France Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 51. UK Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 52. Italy Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 53. Russia Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 54. Middle East & Africa Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Figure 55. Middle East & Africa Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Figure 56. Middle East & Africa Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Figure 57. Egypt Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 58. South Africa Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 59. Israel Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 60. Turkey Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 61. GCC Countries Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 62. Americas Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 63. APAC Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 64. Europe Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 65. Middle East & Africa Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 66. United States Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 67. Canada Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 68. Mexico Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 69. Brazil Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 70. China Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 71. Japan Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 72. Korea Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 73. Southeast Asia Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 74. India Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 75. Australia Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 76. Germany Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 77. France Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 78. UK Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 79. Italy Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 80. Russia Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 81. Egypt Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 82. South Africa Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 83. Israel Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 84. Turkey Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 85. Global Targeted Alpha-particle Therapy Market Size Market Share Forecast by Type (2027-2032)
Figure 86. Global Targeted Alpha-particle Therapy Market Size Market Share Forecast by Application (2027-2032)
Figure 87. GCC Countries Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 1. Targeted Alpha-particle Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Alpha-particle Therapy Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted Alpha-particle Therapy Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted Alpha-particle Therapy Sales Market Share by Country/Region (2025)
Figure 8. Targeted Alpha-particle Therapy Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted Alpha-particle Therapy Market Size Market Share by Type in 2025
Figure 10. Global Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers in 2025
Figure 11. Global Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target in 2025
Figure 12. Global Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method in 2025
Figure 13. Targeted Alpha-particle Therapy in Immunotherapy
Figure 14. Global Targeted Alpha-particle Therapy Market: Immunotherapy (2021-2026) & ($ millions)
Figure 15. Targeted Alpha-particle Therapy in Peritoneal Carcinomas
Figure 16. Global Targeted Alpha-particle Therapy Market: Peritoneal Carcinomas (2021-2026) & ($ millions)
Figure 17. Targeted Alpha-particle Therapy in Bone Metastases
Figure 18. Global Targeted Alpha-particle Therapy Market: Bone Metastases (2021-2026) & ($ millions)
Figure 19. Targeted Alpha-particle Therapy in Leukaemia
Figure 20. Global Targeted Alpha-particle Therapy Market: Leukaemia (2021-2026) & ($ millions)
Figure 21. Targeted Alpha-particle Therapy in Melanomas
Figure 22. Global Targeted Alpha-particle Therapy Market: Melanomas (2021-2026) & ($ millions)
Figure 23. Targeted Alpha-particle Therapy in Solid Tumours
Figure 24. Global Targeted Alpha-particle Therapy Market: Solid Tumours (2021-2026) & ($ millions)
Figure 25. Global Targeted Alpha-particle Therapy Market Size Market Share by Application in 2025
Figure 26. Global Targeted Alpha-particle Therapy Revenue Market Share by Player in 2025
Figure 27. Global Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Figure 28. Americas Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 29. APAC Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 30. Europe Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 31. Middle East & Africa Targeted Alpha-particle Therapy Market Size 2021-2026 ($ millions)
Figure 32. Americas Targeted Alpha-particle Therapy Value Market Share by Country in 2025
Figure 33. United States Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 34. Canada Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 35. Mexico Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 36. Brazil Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 37. APAC Targeted Alpha-particle Therapy Market Size Market Share by Region in 2025
Figure 38. APAC Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Figure 39. APAC Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Figure 40. China Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 41. Japan Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 42. South Korea Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 43. Southeast Asia Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 44. India Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 45. Australia Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 46. Europe Targeted Alpha-particle Therapy Market Size Market Share by Country in 2025
Figure 47. Europe Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Figure 48. Europe Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Figure 49. Germany Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 50. France Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 51. UK Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 52. Italy Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 53. Russia Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 54. Middle East & Africa Targeted Alpha-particle Therapy Market Size Market Share by Region (2021-2026)
Figure 55. Middle East & Africa Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2026)
Figure 56. Middle East & Africa Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2026)
Figure 57. Egypt Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 58. South Africa Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 59. Israel Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 60. Turkey Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 61. GCC Countries Targeted Alpha-particle Therapy Market Size Growth 2021-2026 ($ millions)
Figure 62. Americas Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 63. APAC Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 64. Europe Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 65. Middle East & Africa Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 66. United States Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 67. Canada Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 68. Mexico Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 69. Brazil Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 70. China Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 71. Japan Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 72. Korea Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 73. Southeast Asia Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 74. India Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 75. Australia Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 76. Germany Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 77. France Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 78. UK Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 79. Italy Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 80. Russia Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 81. Egypt Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 82. South Africa Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 83. Israel Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 84. Turkey Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
Figure 85. Global Targeted Alpha-particle Therapy Market Size Market Share Forecast by Type (2027-2032)
Figure 86. Global Targeted Alpha-particle Therapy Market Size Market Share Forecast by Application (2027-2032)
Figure 87. GCC Countries Targeted Alpha-particle Therapy Market Size 2027-2032 ($ millions)
